Qiagen

Qiagen is one of the world's largest manufacturers of molecular diagnostics equipment. It employs about 5,100 people who work in 35 offices in more than 25 countries (as of March 2020). The company's sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples, which allows the detection of cancer and coronavirus in humans. Special technologies are used to enrich these samples to make biomolecules readily available for analysis. In addition, Qiagen's tools can be used to automate these workflows, while its bioinformatics systems allow customers to continuously monitor the process.

Performance indicators

The company's revenue for 2019 amounted to $1.53 billion.

History

2021: Recovery of 33 million rubles in favor of the Russian company InterLabService

In December 2021, the Ninth Arbitration Court of Appeal of Moscow rejected the appeal against the decision of the court of first instance in the case of disruption of the supply of medical equipment LLC "Kaijen Rus" (represents the holding Qiagen N.V registered in Holland in Russia). The plaintiff in this case was the company "InterLabService," which is engaged in the supply of high-tech products for molecular diagnostics in Russia and the CIS countries.

The essence of the claims is as follows. Kaijen Rus was obliged to supply InterLabService with 100 real-time polymerase chain reaction (PCR) devices Rotor-Gene Q with accessories (Rotor-Gene Q 6plex) within 45 days after invoicing. The supplier billed on March 2, 2020, and a week later recalled it "due to the growth of the euro against the ruble."

Real-Time Polymerase Chain Reaction (PCR) Device Rotor-Gene Q

As a result, InterLabService was forced to terminate a number of government contracts or supply more expensive equipment at its own expense, the lawsuit says. Lawyer Petr Lyalin, representing the interests of InterLabService LLC, said that Kaijen Rus's refusal of contractual obligations led to a lack of equipment for PCR diagnostics by medical institutions during the pandemic. Also, InterLabService appealed to the court with a claim for damages.

The court fully satisfied the claims and decided to recover from Kaijen Rus a contractual penalty for late goods in the amount of 10.6 million rubles, losses in the amount of almost 22.7 million rubles. and state duty costs of 190 thousand rubles. The total amount of claims amounted to 33,322,541 rubles.

We are satisfied with both the decision of the court of first instance and the decision of the court of appeal. The courts gave a fair and clear assessment of the illegal actions of Kaijen Rus, which illegally refused to supply goods to InterLabService, thereby endangering the national interests of the Russian Federation, its citizens and the health care system, - said Pyotr Lyalin.

2020: Thermo Fisher Scientific bought the company for $11.5 billion

In early March 2020, it became known that Thermo Fisher Scientific was buying Qiagen NV. The Qiagen Governing Council unanimously approved Thermo Fisher's offer to acquire the company for €39 euros per share, the transaction will be paid for by the buyer's own funds (without attracting his shares). With such a deal, the price of QIAGEN will be approximately $11.5 billion.

Thermo Fisher Scientific buys Qiagen NV

The acquisition is expected to expand Thermo Fisher's range of specialized diagnostics by adding molecular diagnostic capabilities for a variety of diseases, including infectious (including coronavirus), allergic, autoimmune and oncological. The combined company will accelerate the development of more specific, faster and more comprehensive tests that can improve patient outcomes and reduce the cost of health care.

Thermo Fisher will be able to expand customer access to Qiagen's product portfolio through established connections in a number of the world's largest markets. In addition, given Thermo Fisher's presence in high-growth and emerging markets, Qiagen will be able to continue to penetrate previously undeveloped regions.^[1]

Notes